Pathways activated in most K9 bone tumors not driving the worst bone tumors
"We split the samples into two groups: poor responders who had gone less than 100 days after treatment before the progression of their disease, and strong responders who had made it more than 300 days after their treatment without disease progression. Then we could explore the genetic differences between these two groups," says Dawn Duval, PhD, CU Cancer Center investigator and associate professor of molecular oncology at Colorado State University. Specifically, Duval and colleagues including first author Deanna Dailey, DVM, looked at the expression of a protein called HES1, which is used as a proxy to test for NOTCH activation. High HES1 means that upstream, NOTCH is firing…